EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fabrication and appraisal of targeted axitinib loaded bilosomes for the enhanced breast and ovarian anticancer activity

Randa Mohammed Zaki iD, Basmah Nasser Aldosari iD, Layla A Alkharashi, Alyaa Alsalhi iD, Fatma I Abo El-Ela, Raneem Meshal Alosaimi, Maha Alsunbul, Obaid Afzal iD, Mayada Said

PLOS One · 2025

DOI: 10.1371/journal.pone.0325511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Randa Mohammed Zaki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia. Hauptthemen laut MEDLINE: Axitinib, Breast Neoplasms, Antineoplastic Agents, Ovarian Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research, Prince Sattam bin Abdulaziz University, Deanship of Scientific Research, Princess Nourah Bint Abdulrahman University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The goal of this study was the formulation and optimization by statistical means of bilosomal formulations of axitinib (AXT) in order to improve its anticancer efficacy in a targeted manner. A central composite rotatable design was employed Using Design-Expert® software. The formulation factors were cholesterol, span 60, and sodium deoxy cholate (SDC) amounts (mg), whereas the dependent responses were Entrapment efficiency (EE%), Vesicles’ size (VS), and Zeta potential (ZP). The design expert software was utilized to perform the numerical optimization process. The optimized bilosomal formulation was assessed using differential scanning calorimetry (DSC), X-ray diffraction (XRD), transmission electron microscope (TEM), in-vitro release study, short-term stability study, and in-vitro cell proliferation assay and flow cytometry on MCF-7 breast and OV-2774 ovarian cancer cell lines. The optimized formulation was found to be composed of 19.999, 111.869 and 15 mgs of cholesterol, span 60, and SDC, respectively with a desirability of 0.753. EE%, VS, and ZP were predicted to be 88.4977%, 594.592 nm, and −44.2354 mV, respectively. The validation process on the optimized formula demonstrated that the variation from the predicted responses was less than 5%. The DSC and XRD studies revealed that AXT was entrapped within the bilosomal vesicles. The optimized AXT bilosomal formulation exhibited spherical non-aggregated nanovesicles in TEM images. Furthermore, it improved AXT release when compared to AXT suspension. According to stability experiments, the optimum bilosomal formulation was stable for thirty days. The cytotoxicity of the optimized bilosomal formulation was enhanced on the MCF-7 breast and OV-2774 ovarian cancer cell lines compared to AXT suspension even at lower concentrations. Flow cytometry showed that AXT loaded BSMs made a significant increase in the percentage of apoptotic cells in MCF-7 and OV-2774 cells, respectively. Molecular docking suggests that axitinib and SDC decreased the activation of the caspase-8 receptor on the surface of ovarian and breast cancer, which consequently led to an increase in anticancer activity. So, BSMs might be regarded a promising carrier of AXT to target ant treat breast and ovarian cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AxitinibBreast NeoplasmsAntineoplastic AgentsOvarian NeoplasmsLiposomesHumansFemaleMCF-7 CellsCell ProliferationCell Line, TumorApoptosisDrug LiberationParticle Size

Substanzen

AxitinibAntineoplastic AgentsLiposomes

Autor:innen und Institutionen

  • Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
  • Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
  • Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  • Department of Pharmacology and toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  • Department of pharmacology, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef, Egypt.
  • Department of Pharmaceutical Sciences., College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

ORCID-Profile: Randa Mohammed Zaki, Basmah Nasser Aldosari, Alyaa Alsalhi, Obaid Afzal

Förderung

  • Deanship of Scientific Research, Prince Sattam bin Abdulaziz University
  • Deanship of Scientific Research, Princess Nourah Bint Abdulrahman University

Zitieren

APA

Zaki, R. M., Aldosari, B. N., Alkharashi, L. A., Alsalhi, A., Abo El-Ela, F. I., Alosaimi, R. M., Alsunbul, M., Afzal, O., & Said, M. (2025). Fabrication and appraisal of targeted axitinib loaded bilosomes for the enhanced breast and ovarian anticancer activity. PLOS One. https://doi.org/10.1371/journal.pone.0325511

Vancouver

Zaki RM, Aldosari BN, Alkharashi LA, Alsalhi A, Abo El-Ela FI, Alosaimi RM, et al. Fabrication and appraisal of targeted axitinib loaded bilosomes for the enhanced breast and ovarian anticancer activity. PLOS One. 2025. doi:10.1371/journal.pone.0325511

BibTeX
@article{Zaki2025,
  author = {Zaki, Randa Mohammed and Aldosari, Basmah Nasser and Alkharashi, Layla A and Alsalhi, Alyaa and Abo El-Ela, Fatma I and Alosaimi, Raneem Meshal and Alsunbul, Maha and Afzal, Obaid and Said, Mayada},
  title = {Fabrication and appraisal of targeted axitinib loaded bilosomes for the enhanced breast and ovarian anticancer activity},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0325511}
}
Kostenlos starten →